These concepts warrant further investigation in ESCC, particularly considering the poor outcome of these patients and the unsuitability of EGFR-positive tumours for treatment with immune checkpoint inhibitors. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.